Seventeen compounds, one row each. An advisory committee voted on seven peptides in July 2026 and the internet has been describing that vote as though it settled the law. It did not. This page states where each compound actually stands, and carries a date so you can tell when it stops being current.
Last updated 25 September 2026 · Votes verified against the committee record| Compound | Status | FDA approval | July 2026 committee | 503A Bulks List | Note |
|---|---|---|---|---|---|
| SemaglutideOzempic, Wegovy | Approved | Approved | Not applicable | Not applicable | An approved drug. The 503A compounding question does not apply to it. |
| TirzepatideMounjaro, Zepbound | Approved | Approved | Not applicable | Not applicable | An approved drug. Dual GIP and GLP-1 receptor agonist. |
| LiraglutideSaxenda, Victoza | Approved | Approved | Not applicable | Not applicable | Approved, and commercially in retreat as newer agents take the market. |
| TesamorelinEgrifta | Approved | Approved since 2010 | Not applicable | Not applicable | Approved for HIV-associated lipodystrophy only. The label dose is 1.4 mg. The pages that rank for it recommend other numbers. |
| BPC-157Body Protection Compound 157 | Recommended, not law | Not approved | In favour, 8 to 6 with 1 abstention | Not on it. Removed from Category 2 on 15 April 2026. | No published randomised controlled trial in humans for any indication. |
| KPVLysine-proline-valine | Recommended, not law | Not approved | In favour, 8 to 6 | Not on it. | A tripeptide fragment of alpha-MSH. Recommended, not listed. |
| TB-500Thymosin beta-4 fragment | Recommended, not law | Not approved | In favour, 8 to 6 | Not on it. | Often discussed as interchangeable with thymosin beta-4. It is a fragment of it. |
| MOTS-cMitochondrial ORF of the 12S rRNA type-c | Recommended, not law | Not approved | In favour, 7 to 5 with 2 abstentions | Not on it. | A mitochondrial-derived peptide. The narrowest margin of the six that passed. |
| EpitalonEpithalon, AEDG peptide | Recommended, not law | Not approved | In favour, 7 to 4 | Not on it. | Carries the largest longevity claims and the thinnest human evidence base. |
| SemaxACTH(4-10) analogue | Recommended, not law | Not approved | In favour, 8 to 5 | Not on it. | Registered as a medicine in Russia. That is not an FDA approval. |
| EmideltideDSIP, delta sleep-inducing peptide | Recommended against | Not approved | Against, 6 to 7 | Not on it, and recommended against. | The only one of the seven the committee voted down. |
| SermorelinGeref | Neither | Formerly approved as Geref. No approved product today. | Not among the seven reviewed | Not on it, and not in the interim categories. | Discontinued by the manufacturer in 2008. Compounded today under a different pathway. |
| CJC-1295 | Neither | Not approved | Not among the seven reviewed | Not on it. | Not reviewed in July 2026. Its status did not change that week. |
| Ipamorelin | Neither | Not approved | Not among the seven reviewed | Not on it. | Not reviewed in July 2026. Its status did not change that week. |
| GHK-CuCopper peptide | Neither | Not approved as a drug | Not among the seven reviewed | Not on it. | Widely sold in cosmetics, which is a different regulatory category entirely. |
| 5-Amino-1MQ | Neither | Not approved | Not among the seven reviewed | Not on it. | Searches grew about 1,400 per cent. Its legal status did not move at all. |
| Melanotan II | Neither | Not approved | Not among the seven reviewed | Not on it. | Not reviewed in July 2026. Its status did not change that week. |
Nothing matches that filter.
This table only matters because it is current. When the FDA opens rulemaking, publishes a rule, or a committee votes again, this page changes that day and you get one email saying exactly which row moved and why. Nothing else.
Every column here is regulatory. A compound appearing as recommended means a committee voted for it to be available for pharmacy compounding. It does not mean the compound is safe, that it works, or that it is appropriate for anyone in particular. Those are separate questions and this table does not answer them.
Nothing on this page is medical advice or a recommendation to take or avoid anything. Ozemback is an independent publication, not a provider, and takes no part in any clinical decision. Talk to a licensed clinician. See the full terms and editorial disclaimer.
Most people get this wrong, and they get it wrong in the same direction: they assume the July vote made these legal. Ten compounds, one question each.